RxDoctor Payments DataLook up a doctor →

Marvin Bishop, MD

Endocrinology, Diabetes & Metabolism · Pikeville, KYNPI 1578533766

Payments from drug & device makers

$13,839in general payments, 2019–2025

Across 423 payments — averaging $32.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • USWM, LLC$5K
  • AbbVie$4K
  • Amgen$603
  • Johnson & Johnson$538
  • EPI Health, LLC$510
  • Pfizer$386
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$9,53669%
  • Education$2662%
  • Gifts$4,03729%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,839 in reported general payments places this provider in the 70th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky

Medicare billing

Part B allowed, 2024
$195,440
Medicare patients
558
Services billed
3,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Triamcinolone Acetonide657$6,019
Imiquimod150$5,649
Minocycline Hcl202$4,975
Ketoconazole206$3,051
Levothyroxine Sodium182$2,307
SynthroidLevothyroxine Sodium16$1,753
Clobetasol Propionate21$977
Liothyronine Sodium13$622
Hydrocortisone114$602
Fluocinonide14$501
Acyclovir26$353
Terbinafine Hcl24$249
Methimazole22$248
Methylprednisolone31$133
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$3,582$1,75316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

Other endocrinology, diabetes & metabolism in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →